BURLINGTON, MA, October 1, 2003—Cognos (Nasdaq: COGN; TSX: CSN), the world leader in business intelligence (BI) and corporate performance management, today announced Fujisawa GmbH, European Headquarters of Fujisawa Pharmaceutical Co., Ltd., a world class leader in the pharmaceutical industry with a focus on immunology and inflammation as well as infectious, metabolic and cerebral disease research, has deployed Cognos ReportNet. Today in a production environment, Fujisawa Europe benefits from Cognos ReportNet's unrivaled enterprise reporting coverage, multilingual support and mission-critical performance.

After conducting an extensive competitive evaluation of leading reporting solutions, Fujisawa GmbH selected Cognos ReportNet to deliver a broad range of enterprise business reports without extensive custom coding and IT intervention. With offices around the world and a headquarters in Japan, European decision makers will use Cognos ReportNet in conjunction with Cognos EBI analysis to deliver multilingual, real time performance information on research and development projects from Oracle transactional systems, as well as patient recruitment information for clinical trials. In addition, the finance department will use Cognos ReportNet to facilitate critical strategic planning and forecasting.

"Cognos ReportNet will allow Fujisawa to standardize all of our reporting requirements on a single solution, and significantly reduce the time to author key reports for business user consumption. The key for us was the 'self-service' nature of the Cognos ReportNet authoring environment. The drag and drop functionality will enable our business users to create the reports they need in minutes," said Nicola Marangoni, business intelligence/data warehouse manager, Fujisawa GmbH. "Cognos ReportNet's easy authentication and open security also set Cognos apart given the sensitivity of our data."

The flexibility of Cognos ReportNet's report authoring environment allows IT and business decision-makers to create highly customized and compound reports enabling active applications to be embedded. The result is an environment where business users can actively modify and consume reports that give them a 360-degree view of corporate performance, including integrated access into multidimensional OLAP cubes, enabling powerful drill-through capabilities.

"At Fujisawa GmbH, the business user feedback has been quite positive. While IT was active in the selection process, our business stakeholders were pleased about the selection of Cognos ReportNet due to its ease of use," added Marangoni.

Designed to scale to 100s of 1,000s of users, Cognos ReportNet solution draws upon Cognos reporting and query leadership to deliver the next evolution of reporting. Cognos ReportNet is fully integrated with the Cognos Enterprise BI solution, including flexible scorecards, dashboards, powerful industry-leading OLAP analysis, event detection and alerting, and data integration.

"Global leaders like Fujisawa are turning to Cognos ReportNet as a solution that will allow for global-scale deployment. Driving to a production environment in less than one month, Cognos ReportNet continues to provide its exceptional enterprise performance and business user ease of use," said Dave Laverty, senior vice president, global marketing, Cognos.

ABOUT FUJISAWA
More than a Century of Commitment to Pharmaceutical Innovation: Founded as a small medicine store in 1894 in Osaka, Japan, Fujisawa has grown to become one of the world's top 30 pharmaceutical corporations. Underlying this progress has been Fujisawa's continuing commitment to the discovery, research, development and marketing of innovative pharmaceutical therapies.

The international network of offices, manufacturing plants and research facilities in North America, Europe and Asia currently employs a total workforce of approximately 8,300 people. Fujisawa's core business is its line of ethical pharmaceutical products, which account for approximately 85% of net sales. The company's R&D activities focus on areas with a high therapeutic need: dermatology, immunology/inflammation, cerebral diseases, metabolic diseases and infectious diseases.

The worldwide presence of Fujisawa has grown significantly since the introduction of the immunosuppressant Prograf®, indicated to prevent graft rejection after liver and kidney transplantation. One of the most recent market introductions is the global launch of Protopic®, which is the first in a new class of agents known as topical immunomodulators (TIMs), and is indicated for patients suffering from atopic dermatitis.

Fujisawa also produces a wide range of antibiotics and biological products, including cephalosporin antibiotics and the novel antifungal agent micafungin. Other product categories include medicines for use in cardiovascular and respiratory diseases, gastroenterology and neurology, as well as anti-allergic agents.